The total return for Merck & Co., Inc. (MRK) stock is +56.29% over the past 12 months vs. +24.34% for the S&P 500. So far it's up +14.46% this year. Includes price appreciation + reinvested dividends.
Merck & Co., Inc. (MRK) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +50.81% | +2.61% | +10.07% | +8.17% | +8.68% | +6.77% |
| Total Return CAGR | +56.29% | +5.80% | +13.58% | +11.55% | +12.30% | +10.52% |
| Revenue CAGR | +2.47% | +4.26% | +8.60% | +5.23% | +2.37% | +5.60% |
| Net Income CAGR | (48.77%) | (11.81%) | +4.92% | +6.83% | +12.12% | +3.18% |
| EPS CAGR | +7.99% | +8.40% | +21.21% | +16.39% | +24.28% | +6.40% |
| Free Cash Flow CAGR | (17.17%) | +7.82% | +15.69% | +2.58% | +2.66% | +4.10% |
| Operating Cash Flow CAGR | (14.32%) | +4.51% | +9.55% | +3.82% | +3.19% | +4.39% |
| Dividends CAGR | +5.13% | +5.41% | +6.75% | +6.62% | +5.59% | +4.16% |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
MRK Total Return CAGR Chart
Merck & Co., Inc. (MRK)
Annual Total Returns Comparison
| Year | Start Value | End Value | MRK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 917.81 | 1050.52 | +14.46% | +8.38% | +6.08% |
| 2025 | 836.02 | 917.81 | +9.78% | +17.72% | (7.94%) |
| 2024 | 891.83 | 836.02 | (6.26%) | +24.89% | (31.15%) |
| 2023 | 883.03 | 891.83 | +1.00% | +26.19% | (25.19%) |
| 2022 | 591.11 | 883.03 | +49.38% | (18.17%) | +67.55% |
| 2021 | 580.59 | 591.11 | +1.81% | +28.74% | (26.93%) |
| 2020 | 625.68 | 580.59 | (7.21%) | +18.37% | (25.58%) |
| 2019 | 511.77 | 625.68 | +22.26% | +31.22% | (8.96%) |
| 2018 | 365.51 | 511.77 | +40.01% | (4.56%) | +44.57% |
| 2017 | 370.98 | 365.51 | (1.47%) | +21.70% | (23.17%) |
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis